Treatment of lupus nephritis using laquinimod
First Claim
1. A method of treating a subject afflicted with active lupus nephritis comprising administering to the subject daily between 0.5-1.0 mg of laquinimod or pharmaceutically acceptable salt thereof and between 1-3 g of mycophenolate mofetil, wherein the amount of laquinimod and the amount of mycophenolate mofetil when taken together are more effective to treat he subject than when each agent is administered alone.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis.
66 Citations
15 Claims
- 1. A method of treating a subject afflicted with active lupus nephritis comprising administering to the subject daily between 0.5-1.0 mg of laquinimod or pharmaceutically acceptable salt thereof and between 1-3 g of mycophenolate mofetil, wherein the amount of laquinimod and the amount of mycophenolate mofetil when taken together are more effective to treat he subject than when each agent is administered alone.
Specification